Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-ALXN2050 in Healthy Males
NCT04609670Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Mass Balance Recovery In Urine And Feces After a Single Oral Dose Of [14C]-ALXN2050, Plasma Pharmacokinetics (PK) Of Total Radioactivity: Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) and 8 more. Started Apr 2021; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NCT04609670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609670.